Patient safety and healthcare quality of U.S. laboratory developed tests (LDTs) in the AI/ML era of precision medicine

• Published in: Frontiers in molecular biosciences Vol. 11; p. 1407513
• Main Author: Kurnat-Thoma, Emma L.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 05.08.2024
• Subjects: CMS clinical laboratory improvement amendments (CLIA); FDA proposed rule; genomic tests; laboratory developed tests (LDTs); Molecular Biosciences; regulatory compliance; return of results (RoR)
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2024.1407513

This policy brief summarizes current U.S. regulatory considerations for ensuring patient safety and health care quality of genetic/genomic test information for precision medicine in the era of artificial intelligence/machine learning (AI/ML). The critical role of innovative and efficient laboratory developed tests (LDTs) in providing accurate diagnostic genetic/genomic information for U.S. patient- and family-centered healthcare decision-making is significant. However, many LDTs are not fully vetted for sufficient analytic and clinical validity via current FDA and CMS regulatory oversight pathways. The U.S. Centers for Disease Control and Prevention’s Policy Analytical Framework Tool was used to identify the issue, perform a high-level policy analysis, and develop overview recommendations for a bipartisan healthcare policy reform strategy acceptable to diverse precision and systems medicine stakeholders.